Individuals experiencing fatigue, slow recovery, weight management challenges, or signs of age-related decline may benefit
In obesity, Novos Wegovy (semaglutide injection) was approved in 2021, however uptake has been hindered by access limitations, with no Medicare coverage and limited coverage among commercial plans
in 2023, they showed that SLC25A39 is not only a transporter but a dynamic sensor that regulates the amount of glutathione in the mitochondria and adjusts those levels accordingly
In clinical documentation, discomfort at the injection site, and erythema at the injection site are listed as recognized adverse effects of semaglutide (StatPearls, Semaglutide , NBK603723, NIH)
Prescribing Ozempic for obesity is permissible but considered off-label